The Zacks Analyst Blog Highlights: Boeing, Texas Instruments, Bristol-Myers, Estee Lauder and Travelers

For Immediate Release

Chicago, IL – March 28, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boeing BA, Texas Instruments TXN, Bristol-Myers BMY, Estee Lauder EL and Travelers TRV.

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for Boeing, Texas Instruments and Bristol-Myers

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boeing, Texas Instruments and Bristol-Myers. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Strong Buy-rated Boeing’s shares have surged +86.8% in the last year, outperforming the Zacks Aerospace & Defense sector, which gained +48.4% during the same time period. The Zacks analyst stresses that Boeing is the largest aircraft manufacturer in the world in terms of revenues, orders and deliveries. In this regard, the company’s 20-year market outlook forecasts commercial jetliner demand to increase by 3.6%.

Boeing expects single-aisle jets to be the major driver behind this demand growth. Meanwhile, Middle East has emerged as another promising market for Boeing. Yet, this aerospace company continues to face challenges from stiff competition.

Shares of Buy-rated Texas Instruments have gained +32.3% in the last year, underperforming the Zacks General Semiconductor industry which has gained +62.1% over the same period. The Zacks analyst likes the fact that the company continues to prudently invest its R&D dollars in several high margin, high-growth areas of the analog and embedded processing markets. This is gradually increasing its exposure to industrial and automotive markets and dollar content at customers, while reducing exposure to volatile consumer/computing markets.

Margins continue to expand on secular strength in the auto and industrial markets and manufacturing efficiencies that include growing 300-millimeter Analog output. Continuous dividend hike is a big positive. However, increasing competition, unfavorable currency effect and a high debt load remain concerns.

Bristol-Myers’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry in the last one year, gaining +12.8% vs. +4.2%. Bristol-Myers’ blockbuster drug Opdivo continues to perform well along with Eliquis. The guidance for 2018 was encouraging as well. The Zacks analyst likes Bristol-Myers’ efforts to develop its pipeline, especially Opdivo. Several label expansion applications for Opdivo are under review in the United States and Europe. Potential approval will boost the prospects of these drugs.

The positive results from the Checkmate-227 study for first-line treatment of lung cancer has already boosted prospects of approval. However, pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain an overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to the adoption of Opdivo in adjuvant melanoma.

Other noteworthy reports we are featuring today include Estee Lauder and Travelers.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                       

https://www.zacks.com                                                   

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
The Boeing Company (BA) : Free Stock Analysis Report
 
The Estee Lauder Companies Inc. (EL) : Free Stock Analysis Report
 
The Travelers Companies, Inc. (TRV) : Free Stock Analysis Report
 
Texas Instruments Incorporated (TXN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research